A pilot study of human interferon beta gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes.

BACKGROUND Cationic liposomes containing the human interferon beta (HuIFNbeta) gene (IAB-1) was used for the clinical trial for glioma patients. HuIFNbeta gene therapy showed much higher anti-tumor activity compared with the administration of HuIFNbeta protein for melanoma. These results suggest that HuIFNbeta gene therapy is an attractive strategy for the treatment of melanoma. METHODS Stage IV or III melanoma patients with cutaneous or subcutaneous metastatic lesions were enrolled in this pilot study. IAB-1 was dissolved by sterile PBS at a concentration of 30 microg DNA/ml and was injected into cutaneous or subcutaneous metastatic nodules three times a week for 2 weeks and the effect on the injected and non-injected metastatic lesions was evaluated. RESULTS Clinical responses were as follows (five patients): mixed response (MR) and no change in each one patient, and progressive disease in three patients. In the MR patient, the IAB-1 injected lesion disappeared clinically and histopathologically and one-half of IAB-1 non-injected skin metastases were transiently inflamed and mostly regressed. In the responded non-injected lesions of this patient, histopathologically, infiltration of CD4 positive T cells was observed around the melanoma cells in the dermis, which expressed the HLA-Class II antigen. Adverse events due to this gene therapy were not recognized in any of the patients. CONCLUSIONS The efficacy of this gene therapy was generally insufficient; however, some immunological responses were recognized in one patient. No adverse events were observed. HuIFNbeta gene therapy could be an attractive strategy for treatment of a variety of malignancies, including melanoma, though some modifications should be required.

[1]  T. Saida,et al.  Interferon-β therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells , 2008, Archives of Dermatological Research.

[2]  M. Mizuno,et al.  lnterferon‐β gene therapy for cancer: Basic research to clinical application , 2004 .

[3]  Jun Yoshida,et al.  Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. , 2004, Human gene therapy.

[4]  M. Mizuno,et al.  Interferon-beta gene therapy for cancer: basic research to clinical application. , 2004, Cancer science.

[5]  Katsuaki Sato,et al.  Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2 , 2003, Melanoma research.

[6]  S. Ferrone,et al.  Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  T. Saida,et al.  Growth inhibition of subcutaneous mouse melanoma and induction of natural killer cells by liposome-mediated interferon-β gene therapy , 2003, Melanoma research.

[8]  T. Saida,et al.  Repeated cationic multilamellar liposome-mediated gene transfer enhanced transduction efficiency against murine melanoma cell lines. , 2002, Journal of dermatological science.

[9]  T. Saida,et al.  Growth inhibition of human malignant melanoma transfected with the human interferon-β gene by means of cationic liposomes , 2001, Melanoma research.

[10]  Alain Munafo,et al.  Pharmacokinetics and Pharmacodynamics of IFN-β1a in Healthy Volunteers , 2000 .

[11]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[12]  U. Stierner,et al.  Sensitivity to extrinsically supplied interferon and the endogenous expression of interferon in melanoma cell lines. , 1999, Melanoma research.

[13]  T. Nagatani,et al.  Effect of natural interferon-β on the growth of melanoma cell lines , 1998 .

[14]  T. Nagatani,et al.  Effect of natural interferon-beta on the growth of melanoma cell lines. , 1998, Melanoma research.

[15]  B. Seliger,et al.  TAP off--tumors on. , 1997, Immunology today.

[16]  E. Nabel,et al.  Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Colombo,et al.  Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. , 1995, Melanoma research.

[18]  H. Asada,et al.  Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. , 1994, The Journal of biological chemistry.

[19]  T. Eberlein,et al.  T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Marboe,et al.  Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. , 1993, Journal of immunological methods.

[21]  M. Mihm,et al.  Role of integrin α2β1 (VLA-2) in the migration of human melanoma cells on laminin and type IV collagen , 1993 .

[22]  J. Kirkwood,et al.  Homozygous deletions within human chromosome band 9p21 in melanoma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.